We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Breakthrough Coronavirus Treatment Cures Moderate/Serious COVID-19 Patients within Days

By HospiMedica International staff writers
Posted on 08 Feb 2021
A new coronavirus treatment has helped several moderate-to-serious COVID-19 patients recover from the disease within days in Phase 1 trials, according to a report by The Times of Israel.

The medicine developed by scientists at the Ichilov Medical Center (Tel Aviv, Israel) that moderates immune response and helps prevent deadly cytokine storm allowed 29 out of 30 patients in the trial to leave the hospital within 3-5 days. In what is being hailed as a “huge breakthrough,” all the 30 COVID-19 patients with moderate or worse symptoms who had been administered the EXO-CD24 substance recovered from the disease. The substance uses exosomes, or tiny carrier sacs that shuttle materials between cells, to deliver a protein called CD24 to the lungs in order to fight the cytokine storm and calm down the immune system. The scientists will now begin Phase 2 trial of the medicine which could be a potential game-changer in fighting serious COVID-19 illness.

Illustration
Illustration

“The preparation is inhaled once a day for a few minutes, for five days,” Prof. Nadir Arber who discovered the substance told The Times of Israel. “The preparation is directed straight to the heart of the storm - the lungs - so unlike other formulas… which selectively restrain a certain cytokine, or operate widely but cause many serious side effects, EXO-CD24 is administered locally, works broadly and without side effects.”

Related Links:
Ichilov Medical Center


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Compact C-Arm
Arcovis DRF-C S21

Latest COVID-19 News

Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles

World's First Inhalable COVID-19 Vaccine Approved in China

COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles